PC
ACIU icon

PointState Capital’s AC Immune ACIU Stock Holding History

PointState Capital’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-563,850
Closed -$4.51M – 87
2018
Q3 		$4.51M Sell
563,850
-436,150
-44% -$4.39M 0.06% 97
2018
Q2 		$9.3M Hold
1,000,000
– – 0.11% 104
2018
Q1 		$10.3M Hold
1,000,000
– – 0.11% 96
2017
Q4 		$12.8M Hold
1,000,000
– – 0.12% 91
2017
Q3 		$11.3M Hold
1,000,000
– – 0.1% 103
2017
Q2 		$8.8M Hold
1,000,000
– – 0.1% 88
2017
Q1 		$10.4M Buy
1,000,000
+225,000
+29% +$2.76M 0.11% 96
2016
Q4 		$10.1M Buy
775,000
+350,000
+82% +$4.84M 0.14% 89
2016
Q3 		$7M Buy
+425,000
New +$7.34M 0.07% 96

Other funds holding ACIU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PointState Capital's ACIU Position: Q4 2018 in Review

PointState Capital sold out of AC Immune (ACIU) in Q4 2018, closing a stake of 563,850 shares — an estimated $4.51M sold.

PointState Capital first reported a position in ACIU in Q3 2016 and held it in 9 quarters. The position peaked at $12.8M in Q4 2017. 39 funds tracked by Wall St. Rank hold ACIU as of Q4 2018.

  • PointState Capital reported no remaining AC Immune position as of Q4 2018 after selling out during the quarter.
  • PointState Capital sold 563,850 AC Immune shares in Q4 2018, an estimated $4.51M.
  • PointState Capital first reported a position in AC Immune in Q3 2016 and held it in 9 quarters.
  • PointState Capital's AC Immune position peaked at $12.8M in Q4 2017.
  • 39 funds tracked by Wall St. Rank held AC Immune as of Q4 2018.

Based on PointState Capital's 13F filing for Q4 2018, filed 14 Feb 2019.